title: [Malignant neuroleptic syndrome after haloperidol administration].
abstract: The neuroleptic malignant syndrome (NMS) is a rare complication of antipsychotic therapy. We report on a 65-year-old patient who was treated with haloperidol, diazepam and mirtazapin because of a severe depressive episode with psychotic symptoms. He exhibited most of the signs and symptoms characteristic of NMS, e.g.: hyperthermia, rigidity, elevated creatine phosphokinase, leukocytosis, elevated liver enzymes, reduced consciousness and autonomic nervous system disturbances. A secondary pneumonia was diagnosed 2 days after the onset of the NMS, which might have been due to chest wall rigidity. Intensive care treatment consisted of immediate discontinuation of the offending agent, supportive therapy with rehydratation and catecholamines as well as application of dantrolen. After 23 days of intensive therapy all pathological parameters were normalised and the patient was transferred to an internal ward. Three main theories on the pathogenesis of NMS exist: 1. blockade of central receptors, 2. a skeletal muscle target model and 3. sympathoadrenal hyperactivity. The differential diagnosis includes among others malignant hyperthermia and serotonin syndrome.
authors: Klinik für Anästhesiologie, Universitätsklinikum Hamburg-Eppendorf, Martinistrasse 52, 20246 Hamburg. gerbershagen@uke.uni-hamburg.de
authors: M U
authors: MU
authors: Gerbershagen
authors: W D
authors: WD
authors: Ito
authors: F
authors: F
authors: Wappler
authors: M
authors: M
authors: Fiege
authors: J
authors: J
authors: Schulte am Esch
mesh_terms: D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D002395:Catecholamines / Q000627:therapeutic use; D003422:Critical Care; D003620:Dantrolene / Q000627:therapeutic use; D003866:Depressive Disorder / Q000188:drug therapy / Q000523:psychology; D006220:Haloperidol / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008111:Liver Function Tests; D008297:Male; D009125:Muscle Relaxants, Central / Q000627:therapeutic use; D009459:Neuroleptic Malignant Syndrome / Q000628:therapy*
chemical_list: D014150:Antipsychotic Agents; D002395:Catecholamines; D009125:Muscle Relaxants, Central; D003620:Dantrolene; D006220:Haloperidol